![Charles Li](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 275 088 $ in data 31/05/2026
Dr. Charles Li is a Chief Business Officer at Angel Pharmaceuticals Co., Ltd. and an Independent Director at Ekso Bionics Holdings, Inc. He is on the Board of Directors at Ekso Bionics Holdings, Inc. He received his undergraduate degree from Xi'an Jiaotong University and a doctorate degree from John A Paulson School of Engineering & Applied Sciences.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
0,42% | 20/02/2026 | 14.983 ( 0,42% ) | 275 088 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
Angel Pharmaceuticals Co., Ltd.
 Angel Pharmaceuticals Co., Ltd. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops medicines for treatment of cancer, autoimmune and infectious diseases | Corporate Officer/Principal | 10/10/2020 |
| Società | Posizione | Fine |
|---|---|---|
| EKSO BIONICS HOLDINGS | Direttore/Membro del Consiglio | - |
Attive
Inattive
Società nel listino
Aziende private
| Aziende private | 4 |
|---|---|
Ekso Bionics Holdings, Inc.
 Ekso Bionics Holdings, Inc. Medical SpecialtiesHealth Technology Operates as a robotic exoskeleton company, which designs and develops exoskeletons and wearable robots | Health Technology |
Xi'an Jiaotong University
 Xi'an Jiaotong University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
John A Paulson School of Engineering & Applied Sciences
 John A Paulson School of Engineering & Applied Sciences Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Angel Pharmaceuticals Co., Ltd.
Angel Pharmaceuticals Co., Ltd. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops medicines for treatment of cancer, autoimmune and infectious diseases | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
